Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma

NCT00373347 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 573

Last updated 2026-04-17

No results posted yet for this study

Summary

The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)

Conditions

Sponsors & Collaborators

Principal Investigators

  • Samuel So · Stanford University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2024-11-18
Completion
2024-11-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00373347 on ClinicalTrials.gov